The Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act (H.R. 1840) is a bipartisan bill introduced in the U.S. House of Representatives by Congressman Erik Paulsen (R-MN) and Congressman Mike Thompson (D-CA). The bill would give a tax credit to organizations that create new antibiotics and "rapid diagnostic tests" that treat serious or life-threatening infections. According to the Infectious Diseases Society of America, the legislation's tax credit is modeled after the credit offered under the Orphan Drug Act for treatments of rare diseases.
Attributes | Values |
---|
rdfs:label
| - Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act (en)
|
rdfs:comment
| - The Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act (H.R. 1840) is a bipartisan bill introduced in the U.S. House of Representatives by Congressman Erik Paulsen (R-MN) and Congressman Mike Thompson (D-CA). The bill would give a tax credit to organizations that create new antibiotics and "rapid diagnostic tests" that treat serious or life-threatening infections. According to the Infectious Diseases Society of America, the legislation's tax credit is modeled after the credit offered under the Orphan Drug Act for treatments of rare diseases. (en)
|
name
| - Reinvigorating Antibiotics and Diagnostic Innovation Act (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
sponsored by
| |
dbp:wikiPageUsesTemplate
| |
introducedby
| |
introduceddate
| |
introducedin
| |
committees
| |
fullname
| - To amend the Internal Revenue Code of 1986 to allow a credit against tax for clinical testing expenses for qualified infectious disease drugs and rapid diagnostic tests. (en)
|
has abstract
| - The Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act (H.R. 1840) is a bipartisan bill introduced in the U.S. House of Representatives by Congressman Erik Paulsen (R-MN) and Congressman Mike Thompson (D-CA). The bill would give a tax credit to organizations that create new antibiotics and "rapid diagnostic tests" that treat serious or life-threatening infections. According to Politico, "To encourage research and development, the bill would provide a new 50 percent tax credit for the clinical testing expenses of new antibiotics that treat serious or life-threatening infections and rapid infectious disease diagnostic tests." According to the Infectious Diseases Society of America, the legislation's tax credit is modeled after the credit offered under the Orphan Drug Act for treatments of rare diseases. Paulsen is co-chair of the Congressional Medical Technology Caucus. (en)
|
introduced in the
| |
leghisturl
| |
number of co-sponsors
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is foaf:primaryTopic
of | |